BIOMAT Database Logo BIOMAT Database Logo

Treatment of type II hyperlipoproteinaemia with cholestyramine. 1973

R W Schade, and Laar A van't, and A P Jansen

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001796 Blood Protein Disorders Hematologic diseases caused by structural or functional defects of BLOOD PROTEINS. Blood Protein Disorder,Disorder, Blood Protein,Disorders, Blood Protein,Protein Disorder, Blood,Protein Disorders, Blood
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002792 Cholestyramine Resin A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion. Cholestyramine,Colestyramine,Colestyramin,Cuemid,MK-135,Quantalan,Questran,Cholestyramine Resins,Cholestyramines,Colestyramines,Colestyramins,Cuemids,MK 135,MK135,Quantalans,Questrans,Resin, Cholestyramine,Resins, Cholestyramine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R W Schade, and Laar A van't, and A P Jansen
[On the treatment of hyperlipoproteinaemia type II with cholestyramine (author's transl)].
December 1973, Casopis lekaru ceskych,
R W Schade, and Laar A van't, and A P Jansen
Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
January 1982, Artery,
R W Schade, and Laar A van't, and A P Jansen
Combined effects of probucol and cholestyramine in familial type II hyperlipoproteinaemia.
June 1981, Lancet (London, England),
R W Schade, and Laar A van't, and A P Jansen
A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.
June 1977, British journal of clinical pharmacology,
R W Schade, and Laar A van't, and A P Jansen
Acute effects of cholestyramine on serum lipoprotein concentrations in type II hyperlipoproteinaemia.
January 1978, Atherosclerosis,
R W Schade, and Laar A van't, and A P Jansen
Short term treatment of type II hyperlipoproteinaemia with silymarin.
January 1989, Acta medica Hungarica,
R W Schade, and Laar A van't, and A P Jansen
Type II hyperlipoproteinaemia.
March 1973, Clinics in endocrinology and metabolism,
R W Schade, and Laar A van't, and A P Jansen
The effect of cholestyramine on the elimination of cholesterol as bile acids in patients with hyperlipoproteinaemia type II and IV.
December 1974, European journal of clinical investigation,
R W Schade, and Laar A van't, and A P Jansen
Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
January 1975, Postgraduate medical journal,
R W Schade, and Laar A van't, and A P Jansen
Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
January 1975, Postgraduate medical journal,
Copied contents to your clipboard!